The Landmark Series: Chemotherapy for Non-Metastatic Colon Cancer

Predicting Risk of Recurrence After Colorectal Cancer Surgery in the United States: An Analysis of a Special Commission on Cancer National Study

(2020) Syed Nabeel Zafar et al.   ANNALS OF SURGICAL ONCOLOGY

Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration.

(2020) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

(2019) Timothy Iveson et al.   JOURNAL OF CLINICAL ONCOLOGY

FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

(2019) Matthew T. Seymour et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

(2019) Thomas Reinert et al.   JAMA Oncology

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers

(2019) M. Karoui et al.   ANNALS OF SURGERY

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

(2018) Axel Grothey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer

(2016) Leigh Casadaban et al.   CANCER

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study

(2016) David Tougeron et al.   JNCI-Journal of the National Cancer Institute

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study

(2016) David Tougeron et al.   JNCI-Journal of the National Cancer Institute

Identification and Construction of Combinatory Cancer Hallmark–Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer

(2016) Shanwu Gao et al.   JAMA Oncology

Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab

(2016) Julien Taieb et al.   JAMA Oncology

Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial

(2015) Hans-Joachim Schmoll et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line chemotherapy for mCRC—a review and evidence-based algorithm

(2015) Chiara Cremolini et al.   Nature Reviews Clinical Oncology

Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

(2012) Daniel J. Sargent   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

(2012) Aimery de Gramont et al.   LANCET ONCOLOGY

Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue

(2011) Richard D. Kennedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

(2011) Greg Yothers et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

(2011) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

(2011) F. A. Sinicrope et al.   JNCI-Journal of the National Cancer Institute

Relationship Between Tumor Gene Expression and Recurrence in Four Independent Studies of Patients With Stage II/III Colon Cancer Treated With Surgery Alone or Surgery Plus Adjuvant Fluorouracil Plus Leucovorin

(2010) Michael J. O'Connell et al.   JOURNAL OF CLINICAL ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

(2010) Ramon Salazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

(2009) M. Ychou et al.   ANNALS OF ONCOLOGY

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

(2009) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

(2008) Carsten Bokemeyer et al.   JOURNAL OF CLINICAL ONCOLOGY